Hermosilla, Eduardo http://orcid.org/0000-0002-3031-0304
Coma, Ermengol http://orcid.org/0000-0001-8000-3321
Xie, Junqing http://orcid.org/0000-0002-0040-0042
Feng, Shuo http://orcid.org/0000-0001-7855-0991
Cabezas, Carmen
Méndez-Boo, Leonardo http://orcid.org/0000-0002-9215-4378
Fina, Francesc
Ballo, Elisabet
Martínez, Montserrat
Medina-Peralta, Manuel
Argimon, Josep Maria
Prieto-Alhambra, Daniel http://orcid.org/0000-0002-3950-6346
Funding for this research was provided by:
DH | National Institute for Health Research (NIHR Oxford Biomedical Research Centre)
Article History
Received: 12 January 2022
Accepted: 9 March 2022
First Online: 23 March 2022
Competing interests
: D.P.A.’s research group has received research grants from the European Medicines Agency, from the Innovative Medicines Initiative, from Amgen, Chiesi and from UCB Biopharma; and consultancy or speaker fees from Astellas, Amgen, Astra Zeneca and UCB Biopharma. The remaining authors declare no competing interests.